Eton Pharmaceuticals Inc
NASDAQ:ETON

Watchlist Manager
Eton Pharmaceuticals Inc Logo
Eton Pharmaceuticals Inc
NASDAQ:ETON
Watchlist
Price: 15.2 USD -0.33% Market Closed
Market Cap: $407.7m

Net Margin

-9.5%
Current
Improving
by 1.8%
vs 3-y average of -11.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-9.5%
=
Net Income
$-6.7m
/
Revenue
$70.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-9.5%
=
Net Income
$-6.7m
/
Revenue
$70.3m

Peer Comparison

Country Company Market Cap Net
Margin
US
Eton Pharmaceuticals Inc
NASDAQ:ETON
407.6m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
978.7B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
273B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
150.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
95.7B EUR
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
30th
Based on 15 072 companies
30th percentile
-9.5%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Eton Pharmaceuticals Inc
Glance View

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.

ETON Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-9.5%
=
Net Income
$-6.7m
/
Revenue
$70.3m
What is Eton Pharmaceuticals Inc's current Net Margin?

The current Net Margin for Eton Pharmaceuticals Inc is -9.5%, which is above its 3-year median of -11.3%.

How has Net Margin changed over time?

Over the last 3 years, Eton Pharmaceuticals Inc’s Net Margin has increased from -47.2% to -9.5%. During this period, it reached a low of -47.2% on Sep 30, 2022 and a high of 6.8% on Sep 30, 2023.

Back to Top